Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Free Cash Flow: 2014-2024

Historic Free Cash Flow for Protagonist Therapeutics (PTGX) over the last 11 years, with Dec 2024 value amounting to $182.8 million.

  • Protagonist Therapeutics' Free Cash Flow rose 92.93% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.7 million, marking a year-over-year decrease of 72.21%. This contributed to the annual value of $182.8 million for FY2024, which is 358.02% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Free Cash Flow stood at $182.8 million for FY2024, which was up 358.02% from -$70.8 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Free Cash Flow registered a high of $182.8 million during FY2024, and its lowest value of -$109.0 million during FY2021.
  • For the 3-year period, Protagonist Therapeutics' Free Cash Flow averaged around $1.0 million, with its median value being -$70.8 million (2023).
  • Per our database at Business Quant, Protagonist Therapeutics' Free Cash Flow slumped by 71.68% in 2020 and then skyrocketed by 358.02% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' Free Cash Flow (Yearly) stood at -$73.0 million in 2020, then slumped by 49.36% to -$109.0 million in 2021, then grew by 0.03% to -$108.9 million in 2022, then skyrocketed by 34.96% to -$70.8 million in 2023, then surged by 358.02% to $182.8 million in 2024.